Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

By G. Block, K. Martin, A. D. De Francisco, S. Turner, M. Avram, M. Suranyi, G. Hercz, J. Cunningham, A. Abu-Alfa, P. Messa and 12 more. New England Journal of Medicine, 2004

1,087 citations recorded by the source corpus.

Subfields: Nephrology, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/19b54e9e81ae40f60d8ae5f689d2491f91610705

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Kamyar Kalantar-Zadeh
2. N. Kuwae
3. M. Teng
4. M. Wolf
5. D. Regidor
6. R. Kilpatrick
7. C. J. Mcallister
8. M. Norma Ofsthun

Citations in the corpus

• Activated injectable vitamin D and hemodialysis survival: a historical cohort study. (2005, background): “This is especially important given the recent addition of alternative therapies to specifically manage elevated serum levels of PTH (58).”
• Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. (2006, background): “Finally, the studied cohort was before the calcimimetic agent cinacalcet was approved by the Food and Drug Administration.(34) Hence, the relationship between osteodystrophy and survival may be altered in patients receiving cinacalcet starting 2004.”